Despite a slight decrease in mortality over the last decade, breast cancer still remains a leading cause of cancerrelated death in women. Although anti-tumor effects have been observed after allogeneic stem cell transplantation (SCT), this treatment is not standard care owing to graftversus-host disease (GVHD) and scarcity of suitable donors. With the aim of reducing treatment-related mortality and increasing donor availability in clinical situations, we developed a preclinical mouse model that combines nonmyeloablative conditioning with the use of haploidentical donor-recipient pairs. To mimic active disease, CB6F1 mice were inoculated with 5 Â 10 4 4T1 mammary carcinoma cells 10 days before transplantation. Keratinocyte growth factor (KGF) was used as GVHD prophylaxis. Syngeneic (CB6F1) SCT did not cure any of the mice and KGF treatment did not influence tumor development. After transplantation with haploidentical (B6CBAF1) bone marrow and splenocytes, however, tumor outgrowth was reduced and long-term disease-free survival (43 months) was observed in 9/18 (50%) (P ¼ 0.0011) of the animals. We conclude that in a model of murine breast cancer, a graft-versus-tumor effect can be induced by a nonmyeloablative haploidentical SCT procedure.
Introduction
Breast cancer is the most commonly diagnosed malignancy among American and European women. [1] [2] [3] Despite a slight decrease in mortality over the last decade, breast cancer remains one of the leading causes of cancer-related death. 1, 4, 5 Early treatments, applying high-dose chemotherapy followed by autologous bone marrow rescue, showed contradictory results for high-risk metastatic and nonmetastatic breast cancer. 6 Based on a high degree of efficiency in hematological malignancies, 7 allogeneic stem cell transplantation (SCT) was introduced as another possible cure for solid tumors. A graft-versus-tumor (GVT) effect was demonstrated in a few cases after an allogeneic SCT following myeloablative conditioning, [8] [9] [10] but overall success was limited owing to treatment-related toxicity and mortality.
The introduction of reduced-intensity conditioning regimens, causing less morbidity and mortality, 11, 12 made allogeneic transplantation available for a larger number of patients. With this type of treatment, the focus of allogeneic SCT is on eradicating tumor cells by alloreactive cells in the donor graft, instead of attempting to reduce the tumor burden with high doses of chemo-or radiotherapy. Nonmyeloablative conditioning in combination with allogeneic SCT provided favorable results for renal cell carcinoma, [13] [14] [15] and when used for treating breast cancer, 13, 14, 16 a response rate of 26% was accomplished. 17 In all these studies, showing an overall low treatment-related mortality, 17 patients were transplanted with fully human leukocyte antigen (HLA)-matched donor stem cells.
Unfortunately, not all patients eligible for receiving an allogeneic transplant have a fully matched sibling or even unrelated donor, and the use of haploidentical donors, sharing one haplotype with the patient and being mismatched for the other, can substantially limit this problem. However, apart from some case reports [18] [19] [20] and smaller studies, [21] [22] [23] [24] the use of nonmyeloablative conditioning has not extensively been reported for haploidentical donorrecipient combination, and in most cases this treatment was applied for hematological malignancies.
In this paper we describe an animal model of combined nonmyeloablative conditioning and haploidentical SCT, in which the effect on a mouse mammary carcinoma (4T1) is studied. The use of the 4T1 cell line is an established model for metastatic breast cancer and it was previously shown that this tumor type is able to respond to allogeneic treatment [25] [26] [27] in full mismatch or P-F1 mouse combinations. To prevent graft-versus-host disease (GVHD), associated with the immunological mismatch between donor and recipient, the animals were treated with keratinocyte growth factor (KGF). In addition to other groups that report the beneficial effect of KGF in allogeneic transplantation after intense conditioning regimens, 28, 29 we have previously shown that this growth factor can ameliorate and even prevent GVHD in a model of nonmyeloablative haploidentical transplantation. 30 In the current animal model, we observed both a reduced incidence or delay in tumor development and increased survival in mice receiving a haploidentical transplant compared to controls transplanted with syngeneic bone marrow, reflecting tumor cell reduction by allogeneic immune cells. Therefore, we conclude that in this animal model of nonmyeloablative conditioning and haploidentical SCT, that applies KGF as GVHD prophylaxis, breast cancer can be cured. ) hybrid mice were purchased from Harlan Netherlands (Horst, The Netherlands). Animals were 7 or 8 weeks of age. Female and male mice were used as recipients and donors, respectively. Mice were housed in the animal facility of the University of Maastricht and were allowed normal rodent chow and water ad libitum. All experiments had been approved by the Animal Ethics Committee of the University of Maastricht.
Materials and methods

Mice
Mammary carcinoma cell line 4T1 is a tumor cell line established from a spontaneously arising mammary tumor in a Balb/c mouse (haplotype H-2 d ) 31 and was kindly provided by Professor S Slavin (Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Immunobiology Research Center, Hadassah University Hospital, Jerusalem, Israel). 4T1 cells were maintained by in vitro passages in RPMI 1640 containing 300 mg/l L-glutamine and 25 mM HEPES (Invitrogen Ltd, Paisley, UK), supplemented with 10% fetal calf serum (FCS) (Greiner Bio-One GmbH, Frickenhausen, Germany), 1% penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen) and incubated at 371C/5% CO 2 . Cells were harvested with 0.25% trypsin (Invitrogen) and 0.2% EDTA (Merck, Darmstadt, Germany), washed with RPMI 1640 (Invitrogen) containing 10% FCS (Greiner Bio-One) and resuspended in phosphate-buffered saline (PBS) (Sigma-Aldrich Co., St Louis, MO, USA). An end volume of 250 ml, containing 5 Â 10 4 4T1 cells, was injected subcutaneously (s.c.) into the right flank of the animals 10 days before transplantation (day 0). As intravenous administration of the tumor cells lead to very rapid death, hindering assessment of immune effects, s.c. application was chosen to enable objective tumor measurements.
Measurement of tumor growth
Three dimensions of the developing tumor were measured, using calipers, and the tumor volume was calculated as the product of these three values. Mice were killed when the tumor exceeded a volume of 2000 mm 3 or when the tumor penetrated the skin.
Conditioning regimen
All mice received a nonmyeloablative conditioning regimen as described previously. 30 Briefly, conditioning consisted of two fractions of 200 cGy of total body irradiation (TBI) 8 and 9 days after tumor inoculation combined with 200 mg/ kg cyclophosphamide (Cy) on day 9. Animals were placed in a Perspex container, without anesthesia and radiation was delivered by a Philips X-ray unit (225 kV, 10 mA) at a dose rate of 66 cGy/min. Cyclophosphamide (Endoxan), (Baxter Oncology GmbH, Frankfurt, Germany) was obtained from the hospital's pharmacy and further diluted according to the manufacturer's instructions.
Stem cell transplantation
Femora and tibiae of B6CBAF1 donor mice were flushed with RPMI 1640 (Invitrogen) using a 25 G needle. Spleens and flushed marrow were filtered through nylon mesh screens to obtain single-cell suspensions. One day after termination of conditioning (day 10), CB6F1 recipient mice were injected intravenously with 3.3 Â 10 7 donor bone marrow and 1 Â 10 8 unseparated splenocytes.
Graft-versus-host disease prophylaxis and monitoring
Recombinant human KGF (Palifermin) was provided by Amgen Inc. (Thousand Oaks, CA, USA) and dissolved in the supplied reconstitution fluid. Further dilutions were made in PBS (Sigma) before s.c. injection. Treatment with 5 mg/kg/day started 3 days before conditioning (day 5) and was continued till 3 days after transplantation (day 13). Animals were monitored daily for clinical signs of GVHD, that is, weight loss, diarrhea, changes in fur and skin texture and hunched posture.
Determination of chimerism
To determine chimerism, peripheral blood was collected by orbital punction, using heparinized capillaries and suspended in PBS (Sigma) supplemented with 0.1% FCS (Greiner Bio-One) and 0.02% sodium azide (Merck). After preincubation with mouse Fc block for 10 min, cells were incubated with fluorescein isothiocyanate-conjugated
k or rat-antimouse CD19 and PE-Cy5-labeled rat-anti-mouse CD3, for 30 min on ice. All antibodies were purchased from BD Biosciences/Pharmingen (San Diego, CA, USA). After staining, cells were washed and remaining erythrocytes were lysed by means of FACS Lysing Solution (BD). Analysis was performed on a FACSsort cytometer (BD).
Statistics
Results of tumor occurrence were analyzed according to the Student's unpaired t-test. Values are presented as mean7s.e.m. Survival curves were composed using the Kaplan-Meier method and compared with the Mantel-Cox log-rank test. The Fisher's exact test was used to compare differences in tumor development between groups. In all cases, differences were considered statistically significant when probability (P) values were less than or equal to 0.05.
Results
Influence of a nonmyeloablative conditioning regimen on 4T1 development To ascertain that any possible GVT effect could be attributed to alloreactive donor cells and not to the preparative regimen, 4T1-bearing CB6F1 mice were subjected to our standard conditioning protocol and transplantation with syngeneic bone marrow and splenocytes. Eight days after tumor inoculation, animals received a TBI of 200 cGy, followed by another similar radiation dose and 200 mg/kg Cy the next day. One day later, 3.3 Â 10 7 syngeneic BM cells and 1 Â 10 8 splenocytes were infused. This conditioning regimen was previously proven to be nonmyeloablative and to induce stable full donor chimerism when followed by a haploidentical transplantation. 30 Although tumor growth rate varied over experiments, untreated control mice and animals treated with a syngeneic transplant all developed a palpable tumor by day 15.970.9 (n ¼ 12) and day 17.772.9 (n ¼ 15), respectively (P ¼ 0.6086). Control animals developed a tumor of 2 cm 3 by day 38.872.3 (n ¼ 12), whereas animals receiving nonmyeloablative conditioning and a syngeneic transplantation presented with a similar tumor at day 54.278.5 (n ¼ 15) (P ¼ 0.1267). Although results were not significantly different, there seemed to be a slight delay in tumor development after syngeneic SCT. Nevertheless, these experiments demonstrated that a nonmyeloablative preparative regimen, consisting of TBI and Cy, followed by a syngeneic SCT, was never curative.
KGF does not influence the growth rate of 4T1
In a first experiment, comparing syngeneic and haploidentical allogeneic transplantation, we were able to observe a first indication of an allogeneic GVT effect. Whereas in the syngeneic group four out of five animals developed a palpable tumor by day 16 after induction, the first tumor in the allogeneic group only became palpable by day 27. Unfortunately, all allogeneic recipients developed a lethal form of GVHD and further tumor development could not be assessed. Although this delay in tumor development indicated that a GVT effect could be expected in an allogeneic setting, these results also stressed the necessity of an appropriate GVHD prophylaxis. Therefore, in all subsequent experiments, a 9-day KGF treatment was introduced to prevent lethal GVHD.
With this adaptation, it had to be verified whether KGF treatment, starting 5 days after tumor inoculation, had an influence on the growth pattern of the 4T1 tumor. Mice were transplanted with syngeneic BM and splenocytes, following the nonmyeloablative conditioning regimen, and were either treated with PBS or 5 mg/kg KGF for 9 consecutive days. In both groups, animals had to be killed because of tumor size at a median of 41 days, ranging from 35 to 45 days for PBS-treated controls (n ¼ 5) and 35 to 48 days for animals receiving KGF treatment (n ¼ 5). This indicates that KGF treatment does not influence the outgrowth of 4T1 mammary tumors (P ¼ 0.9694).
Haploidentical SCT reduces the incidence and growth rate of 4T1
In order to analyze a possible GVT effect, induced by allogeneic donor stem cells, CB6F1 recipients were treated with nonmyeloablative conditioning and haploidentical B6CBAF1 BM and splenocytes, 10 days after the inoculation of the subcutaneous tumor. Control animals were treated in a similar manner but received a syngeneic transplant. Both animal groups were given a 9-day KGF treatment. Mild dermatitis, limited to the ears or facial area and diminishing 2 weeks after onset, was the only GVHDrelated symptom in our experiments. Animals displayed full donor chimerism in both the T-and B-cell lineages, stable until the end of the observation period.
The results of two separate, but identically performed experiments are shown in Figure 1 .
In the first experiment, five out of five animals receiving a syngeneic transplant developed a tumor (100%), whereas in the allogeneic group, only one out of eight mice (12.5%) showed tumor development (P ¼ 0.0047) (Figure 1a and b) , reflecting a GVT reaction.
Also in the second experiment, a GVT effect could be confirmed. In the syngeneic transplant group, five out of five (100%) animals developed a tumor, but only seven out of ten animals (70%) in the allogeneic group presented with a palpable tumor mass (P ¼ 0.5055) (Figure 1c and d) . Again, a GVT effect was reflected by a delay in tumor development after allogeneic SCT. Whereas the tumorbearing animals in the syngeneic group developed a tumor volume of 2000 mm 3 by day 40.472.5 (n ¼ 5), their haploidentically treated counterparts reached this tumor volume by day 55.773.0 (n ¼ 7) (P ¼ 0.0044).
Where in the first experiment tumors became palpable at day 32.471.6 (n ¼ 5) after inoculation, in the second the tumor was already palpable at day 11.671.8 (n ¼ 5) (Po0.0001). This indicates that in some animals the tumor was already palpable at the time of treatment and that in this latter experiment transplantation occurred when a larger tumor burden was present. Although a smaller group of animals could be cured in this experiment, it shows that even in the case of a larger tumor burden, allogeneic transplantation can reduce the growth rate of the mammary carcinoma. In this second experiment, it was also observed that two of the animals that are tumor-free at the current follow-up time of 164 days, were able to eliminate a palpable tumor. Both animals presented with a palpable mass 13 days after tumor inoculation, but no more tumor could be detected from days 15 and 17 on, proving the fact that not only the conditioning regimen but also donor immune effects are responsible for disappearance of the tumor.
Haploidentical SCT increases survival of tumor-bearing mice To determine whether haploidentical transplantation in 4T1-bearing animals would have an influence on their overall survival, Kaplan-Meier curves were compared for animals of both above-mentioned experiments, in which syngeneic or allogeneic SCT was combined with KGF treatment. In the syngeneic group, nine out of ten animals reached the maximum tumor volume by day 69. Only one animal showed a delayed tumor development, but was eventually killed bearing a large tumor at day 168, bringing the tumor development to 100% in this group (n ¼ 10). In the allogeneic group (n ¼ 18), eight animals developed a progressively growing tumor, one animal remained tumorfree till day 63 when it died of unknown causes and nine animals remained tumor-free until termination of the experiments, 205 and 186 days, respectively. Statistical analysis showed that a treatment consisting of a nonmyeloablative conditioning regimen and haploidentical transplantation yields a significant and clinically relevant (50%) survival advantage, compared to nonmyeloablative conditioning followed by syngeneic transplantation (P ¼ 0.0011) (Figure 2 ).
Discussion
In this paper, we report on the effect of haploidentical transplantation, used as a treatment for murine mammary carcinoma (4T1). Tumor-bearing mice, prepared for haploidentical transplantation with a nonmyeloablative conditioning regimen, displayed a remarkable GVT effect, resulting in increased survival, when compared to animals receiving a syngeneic transplant.
Graft-versus-tumor effects after allogeneic SCT have been reported in various breast cancer patients over the last two decades. Tumor regression was achieved with stem cells from fully HLA-matched related donors, administered after conventional preparative regimens [8] [9] [10] 32 or reducedintensity conditioning. 13, 14, 16, 33 The combined use of nonmyeloablative conditioning and donors mismatched for up to three HLA antigens was, however, limited to patients suffering from a hematological malignancy. 18, [20] [21] [22] [23] [24] A single publication reported a reduction of lung metastases in a patient with renal cell carcinoma, after nonmyeloablative conditioning and haploidentical transplantation. 19 In animal models of 4T1, mimicking human metastatic breast cancer, an anti-tumor response was established as well, although these publications describe fully mismatched 26 or P-F1 25,27 mouse combinations, being less realistic models for the human situation. F1-F1 donorhost combinations provide the best mimic of the clinical haploidentical situation, where donor and recipient share only one haplotype. In these animal reports, various conditioning regimens were used, ranging from lethal irradiation 25 to fractionated combinations of radio-and chemotherapy aimed at preventing GVHD. 26, 27 In some of these publications, 25, 27 irradiation preceded tumor inoculation by 24 h in order to prevent killing of tumor cells. This approach is less suitable to translate into the clinical setting and differs from our conditioning regimen, where the clinical situation of active disease is mimicked by administering both TBI and chemotherapy after tumor inoculation. As this order of treatment indeed includes the risk of eliminating the tumor completely before allogeneic cells are introduced, hence masking a possible GVT effect, tumor-bearing mice were subjected to TBI and Cy before receiving a syngeneic transplant. These experiments revealed that, although results were not statistically different, our nonmyeloablative conditioning regimen might slightly delay tumor development. Simultaneously, it was demonstrated that this treatment never prolonged survival of the animals.
The fact that only in recipients of haploidentical BM and splenocytes a reduction in incidence or delay in tumor evolution could be observed indicates that the GVT effect is indeed mediated by the presence of allogeneic donor cells. Donor T-cells are the most likely effectors in this process, as suggested by the increased relapse rates reported in transplantation studies using T-cell-depleted grafts 34 and the recent finding that donor T -cells are a relevant factor in the anti-tumor response on solid tumors. 35 The possible involvement of alloreactive donor natural killer (NK) cells, 36 although not specifically administered, can however not be excluded. Our transplantation model provides the opportunity to study the immunological mechanisms in more detail and explore the role of NK and T cells in a haploidentical setting, possibly leading to an optimal clinical protocol for treating solid tumors.
The long-term tumor-free survival observed in our experiments proves that the GVT effect exerted by the allogeneic donor cells is able to eradicate a primary tumor, although survival seems to correlate to tumor burden at the time of treatment. Although experiments were performed identically, tumor growth was somewhat variable in this in vivo model. The overall conclusion remains, however, that a GVT effect on murine breast cancer is observed in all experiments. These data confirm the general hypothesis that immunotherapy should be introduced at a time of minimal residual disease, as the presence of a larger tumor burden might suppress immune effector mechanisms.
The choice of using KGF, a growth factor specific for epithelial cells, 37 as GVHD prophylaxis results from our previous experiments, in which KGF is capable of reducing and even preventing GVHD in a model of nonmyeloablative haploidentical transplantation. 30 In those experiments, we also showed that this protection was mediated through the gastrointestinal tract, as described earlier by other groups. 29, 38 Also in the experiments described in this manuscript, animals displayed only very mild forms of GVHD, despite the fact that stable full donor chimerism was established. In continuance of the publication by Krijanovski et al., 29 describing the capability of KGF to separate GVHD from a graft-versus-leukemia effect, we demonstrate here that KGF can prevent GVHD without impairing a GVT effect on murine mammary carcinoma.
The positive results obtained with KGF might be an indication to add this treatment to the standard GVHD prophylaxis in the clinical setting of allogeneic transplantation, however with the necessary precautions. The fact that FGFR2IIIb, the receptor that specifically binds KGF, 39, 40 is present on breast cancer cell lines 41 and that there are reports of increased proliferation and migration in various tumor cells in response to KGF, [42] [43] [44] [45] stresses the necessity to rule out any negative effect this growth factor might have in breast cancer patients. In view of a recent publication, revealing that 4T1 cells express mRNA of FGFR2IIIb, 46 prompted us to study the effect of KGF treatment in mice bearing this tumor. Our results demonstrate that neither tumor development nor survival are influenced by a 9-day KGF treatment in mice receiving a syngeneic transplant and that haploidentical transplantation in combination with KGF can prevent breast cancerinduced death.
We do realize that a positive result in a preclinical mouse model cannot be directly translated into the clinical situation of human metastatic breast cancer and that, before treating patients with this disease with a combination of nonmyeloablative conditioning and haploidentical transplantation, further research is necessary. The most challenging step in this process might be to determine the effector cell responsible for a therapeutic anti-breast cancer effect in this haploidentical transplant model. In the clinic, transplantation protocols are used more frequently in the treatment of hematological diseases, and presently, nonmyeloablative conditioning regimens, resulting in less treatment-related toxicity, are being explored. Hopefully patients with breast cancer might benefit from this treatment option in the near future, as some patients with leukemia already do now.
